Statins and Left Ventricular Ejection Fraction Following Doxorubicin Treatment

Area of Science:

• Cardiology
• Oncology
• Pharmacology

Background:

• Cardiotoxicity from doxorubicin is a concern for breast cancer and lymphoma patients.
• Statins may protect left ventricular ejection fraction (LVEF) in patients with existing cardiovascular conditions.
• The impact of statins on LVEF in patients without cardiovascular indications during doxorubicin treatment is not well understood.

Purpose of the Study:

• To investigate the effect of atorvastatin on LVEF decline in cancer patients undergoing doxorubicin therapy without prior cardiovascular indications.
• To assess whether statin use can mitigate doxorubicin-induced cardiotoxicity in this specific patient population.

Main Methods:

• A 24-month, double-blind, placebo-controlled randomized trial involving 279 patients with breast cancer and lymphoma receiving doxorubicin.
• Participants received either 40 mg of atorvastatin daily or a placebo.
• Cardiac magnetic resonance imaging was used to assess left ventricular (LV) volumes, strain, mass, and LVEF at baseline, 6 months, and 24 months.

Main Results:

• No significant difference in the mean LVEF decline was observed between the atorvastatin group (3.2±0.7 percentage points) and the placebo group (3.3±0.6 percentage points) at 24 months (P=0.93).
• Similar percentages of participants in both groups experienced significant changes in LVEF, LV strain, LV mass, cognition, and inflammation biomarkers.
• These findings held true even for participants with high drug compliance (over 90%).

Conclusions:

• Prospective administration of atorvastatin did not alter LVEF declines in patients with breast cancer and lymphoma who had no pre-existing cardiovascular indications for statin therapy.
• The study suggests that statins may not offer cardioprotective benefits in this specific oncological context.
• Further research may be needed to explore alternative strategies for preventing doxorubicin-induced cardiotoxicity.